Talphera (NASDAQ:TLPH) Raised to Strong-Buy at Maxim Group

Talphera (NASDAQ:TLPH) was upgraded by analysts at Maxim Group to a “strong-buy” rating in a research note issued on Friday,Zacks.com reports.

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Talphera in a research report on Friday, August 16th.

Talphera Stock Down 2.0 %

Shares of TLPH stock opened at $0.89 on Friday. The stock has a 50-day simple moving average of $0.91 and a 200 day simple moving average of $0.94. The stock has a market capitalization of $15.12 million, a P/E ratio of -1.39 and a beta of 0.31. Talphera has a fifty-two week low of $0.43 and a fifty-two week high of $1.61.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, sell-side analysts anticipate that Talphera will post -0.73 earnings per share for the current year.

Hedge Funds Weigh In On Talphera

Institutional investors have recently bought and sold shares of the stock. Turtle Creek Wealth Advisors LLC acquired a new position in Talphera in the 2nd quarter worth approximately $64,000. Nantahala Capital Management LLC purchased a new stake in shares of Talphera in the second quarter valued at $1,773,000. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Talphera in the third quarter worth $650,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.